^
    Back
    Association details:
    Biomarker:STAT6 deletion + HER-2 overexpression
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    STAT6 expression and trastuzumab resistance in HER2+ breast cancer.

    Published date:
    05/28/2020
    Excerpt:
    We observed that loss of STAT6 resulted in resistance to trastuzumab treatment in HER2-over-expressing cells….Loss of STAT6 in breast cells results in enhanced growth properties and resistance to trastuzumab.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e13006